ZIVO Bioscience appoints Board Chairman John Payne as CEO

– USA, MI –  ZIVO Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal, and nutritional product candidates derived from proprietary algal cultures, today announced the appointment of Board Chairman John Payne as President and CEO, succeeding Andrew Dahl.

About John B. Payne

Mr. Payne has served as a member of the ZIVO Board of Directors since July 2013 and as Chairman since December 2019. Mr. Payne was the founder of Compassion-First Pet Hospitals and served as President and CEO from 2014 until 2020. Compassion-First Pet Hospitals, now NVA Compassion-First, is a family of specialty and emergency veterinary hospitals located throughout the United States that is dedicated to changing the veterinary landscape and elevating patient outcomes. Mr. Payne currently serves as Vice-Chairman of National Veterinary Associates, with which Compassion-First Pet Hospitals combined. Before founding Compassion-First, Mr. Payne served as a member of the Global Leadership Team for Mars Pet Care. He also served as President and CEO of Banfield Pet Hospitals and as President and General Manager of Bayer Healthcare’s North American Animal Health Division.

“I am honored to assume the executive leadership of ZIVO Biosciences and expect a seamless transition owing to my 8-1/2 years serving on the Company’s Board of Directors,” said Mr. Payne. “2021 was a year of tremendous progress for our company, and we are proud of the steps we have taken to make inroads on the biotech front, to continue developing our algae technology, to build out the ZIVO management team, and to complete our up-listing to the Nasdaq Capital Market. The ZIVO Board and management team remain focused on the targeted development of both our biotech and agtech business segments, and making progress toward the achievement of revenue.”

Mr. Payne currently serves as Chairman of the Board for American Humane and as Vice-Chairman of the Board of Regents at Ross University School of Medicine and School of Veterinary Medicine. He served on the Board of Directors of Nexvet, a bioscience company located in Dublin, Ireland, through the company’s acquisition by Zoetis in 2018.

About ZIVO Bioscience, Inc.

ZIVO Bioscience is a biotech/agtech company engaged in the investigation of the health and nutritional benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on the general benefits of autoimmune and inflammatory response modulation.

For more information: https://www.zivobioscience.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.